Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,365.09 102.53 0.63%
S&P 500 1,854.10 11.12 0.60%
NASDAQ 4,055.63 21.47 0.53%
Ticker Volume Price Price Delta
STOXX 50 3,128.83 37.31 1.21%
FTSE 100 6,577.50 35.89 0.55%
DAX 9,285.94 112.23 1.22%
Ticker Volume Price Price Delta
NIKKEI 14,417.68 420.87 3.01%
TOPIX 1,166.55 30.46 2.68%
HANG SENG 22,696.01 24.75 0.11%

SDIX Stockholders Approve Sale of Life Science Assets to OriGene Technologies, Inc.



  SDIX Stockholders Approve Sale of Life Science Assets to OriGene
  Technologies, Inc.

Business Wire

NEWARK, Del. -- July 10, 2013

SDIX™ (NASDAQ: SDIX), a leading provider of biotechnology-based products and
services, today announced the results of its Special Meeting of Stockholders
held today. The Company reported that more than 65% percent of the outstanding
shares entitled to vote thereon voted to approve the sale of the assets of the
Company’s Life Sciences and Advanced Technologies businesses to a wholly owned
subsidiary of OriGene.

Stockholders today also voted to approve all of the additional proposals,
including the amendment of the Company’s certificate of incorporation to
change the Company’s name to Special Diversified Opportunities Inc. effective
upon completion of the asset sale, as well as a non-binding proposal regarding
certain transaction-related executive compensation arrangements.

The Company and OriGene expect to close the transaction on July 12, 2013.

This news release may contain forward-looking statements reflecting SDIX’s
current expectations. When used in this press release, words like
“anticipate”, “could”, “enable”, “estimate”, “intend”, “expect”, “believe”,
“can”, “potential”, “will”, “should”, “project”, “plan” and similar
expressions as they relate to SDIX are intended to identify said
forward-looking statements. Investors are cautioned that all forward-looking
statements involve risks and uncertainties, which may cause actual results to
differ from those anticipated by SDIX at this time. Such risks and
uncertainties include, without limitation, changes in demand for products, the
application of our technologies to various uses, delays in product
development, delays in market acceptance of new products, retention of
customers and employees, adequate supply of raw materials, inability to obtain
or delays in obtaining fourth party, or required government approvals, the
ability to meet increased market demand, competition, protection of
intellectual property, non-infringement of intellectual property, seasonality,
and other factors more fully described in SDIX’s public filings with the U.S.
Securities and Exchange Commission.

Contact:

SDIX
Kevin Bratton
Vice President & Chief Financial Officer
302-456-6789
kbratton@sdix.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement